Title:
USE OF PLK4-TARGETING DRUG IN TREATMENT OF PLATINUM DRUG-RESISTANT TUMORS
Document Type and Number:
WIPO Patent Application WO/2024/022080
Kind Code:
A1
Abstract:
A use of a PLK4-targeting drug in the treatment of platinum drug-resistant tumors. Specifically, provided is a use of a PLK4-targeting drug in the preparation of a drug for treating an oxaliplatin-resistant cancer.
More Like This:
Inventors:
FEI TENG (CN)
ZHONG CHUNGE (CN)
LI ZEXU (CN)
ZHONG CHUNGE (CN)
LI ZEXU (CN)
Application Number:
PCT/CN2023/106162
Publication Date:
February 01, 2024
Filing Date:
July 06, 2023
Export Citation:
Assignee:
UNIV NORTHEASTERN (CN)
International Classes:
A61K45/00; A61K31/5377; A61K38/46; A61K48/00; A61P35/00; A61P35/02
Domestic Patent References:
| WO2019113311A1 | 2019-06-13 |
Foreign References:
| CN116850289A | 2023-10-10 | |||
| US20190070190A1 | 2019-03-07 |
Other References:
HE YAO, WANG HUI, YAN MEINA, YANG XINXIN, SHEN RONG, NI XIAOGE, CHEN XIAOKUN, YANG PEIFANG, CHEN MIAO, LU XIAODONG, SHAO GENBAO, Z: "High LIN28A and PLK4 co‑expression is associated with poor prognosis in epithelial ovarian cancer", MOLECULAR MEDICINE REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 18, 1 January 2018 (2018-01-01), GR , pages 5327 - 5336, XP093133093, ISSN: 1791-2997, DOI: 10.3892/mmr.2018.9562
XU ZHAOYING, SUN YONGFA, WANG DANFENG, SUN HUIFANG, LIU XIAOJUN: "SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 20, no. 1, 1 December 2020 (2020-12-01), GB , XP093133111, ISSN: 1475-2867, DOI: 10.1186/s12935-020-01291-y
MANISWAMI RADHIKA RADHA, PRASHANTH SEEMA, KARANTH ARCHANA VENKATARAMANA, KOUSHIK SINDHU, GOVINDARAJ HEMALATHA, MULLANGI RAMESH, RA: "PLK4: a link between centriole biogenesis and cancer", EXPERT OPINION ON THERAPEUTIC TARGETS, INFORMA HEALTHCARE, UK, vol. 22, no. 1, 2 January 2018 (2018-01-02), UK , pages 59 - 73, XP093133115, ISSN: 1472-8222, DOI: 10.1080/14728222.2018.1410140
DUAN ZHENGANG, CAI LEI, CAO JIN, WU WEI: "Polo‑like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer", ONCOLOGY LETTERS, SPANDIDOS PUBLICATIONS, GR, vol. 24, no. 2, 2022, GR , XP093133118, ISSN: 1792-1074, DOI: 10.3892/ol.2022.13389
XU ZHAOYING, SUN YONGFA, WANG DANFENG, SUN HUIFANG, LIU XIAOJUN: "SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 20, no. 1, 1 December 2020 (2020-12-01), GB , XP093133111, ISSN: 1475-2867, DOI: 10.1186/s12935-020-01291-y
MANISWAMI RADHIKA RADHA, PRASHANTH SEEMA, KARANTH ARCHANA VENKATARAMANA, KOUSHIK SINDHU, GOVINDARAJ HEMALATHA, MULLANGI RAMESH, RA: "PLK4: a link between centriole biogenesis and cancer", EXPERT OPINION ON THERAPEUTIC TARGETS, INFORMA HEALTHCARE, UK, vol. 22, no. 1, 2 January 2018 (2018-01-02), UK , pages 59 - 73, XP093133115, ISSN: 1472-8222, DOI: 10.1080/14728222.2018.1410140
DUAN ZHENGANG, CAI LEI, CAO JIN, WU WEI: "Polo‑like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer", ONCOLOGY LETTERS, SPANDIDOS PUBLICATIONS, GR, vol. 24, no. 2, 2022, GR , XP093133118, ISSN: 1792-1074, DOI: 10.3892/ol.2022.13389
Attorney, Agent or Firm:
AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: